Investors like the biotech's promising preclinical data for two experimental COVID antibody therapies. Sorrento Therapeutics and Trillium Therapeutics could both be poised for another explosive move higher. Short-sellers are betting against these stocks big time. But that could set up big opportunities for investors if these biotechs have positive news on the way.
The closing of an acquisition diluted the biotech's shareholders, but that's not the whole story.
Powered by. Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In. Getting Started. Planning for Retirement.
Retired: What Now? Personal Finance. The Ascent. About Us. Who Is the Motley Fool? Fool Podcasts. New Ventures. Search Search:. Interactive Chart. All Market Moves. Company Rating What our community thinks about Sorrento Therapeutics.
CEO Rating The single most important factor in a company's success is the team that's leading the company. Business Summary Industry, sector and description for Sorrento Therapeutics.We want to emphasize there is a cure. There is a solution that works percent. If we have the neutralizing antibody in your body, you don't need the social distancing. You can open up a society without fear.
Is Sorrento Therapeutics Stock a Buy After Its Promising Coronavirus News?
Ji's claims prove accurate, it would be, to put it mildly, a big deal. Medical professionals believe that a relatively large percentage of those who contract the SARS-CoV-2 virus that causes COVID are asymptomatic, and these silent carriers of the virus can still infect others. This factor explains why many are still fearful that there will be a second wave of COVID infections, especially since several states are now beginning to ease social-distancing rules.
Sorrento Therapeutics could reap immense financial benefits if it has indeed found a way to treat and prevent COVID However, investors should remember that until the biotech company demonstrates the efficacy of its product, nothing is set in stone. Investing Best Accounts. Stock Market Basics. Stock Market. Industries to Invest In.
Getting Started. Planning for Retirement.
Why Sorrento Therapeutics Is Skyrocketing Today
Retired: What Now? Personal Finance. The Ascent. About Us. Who Is the Motley Fool? Fool Podcasts. New Ventures.Yahoo Finance. Sign in. Sign in to view your mail.
Finance Home. Sorrento Therapeutics, Inc. Currency in USD. Add to watchlist. Summary Company Outlook. Top Reactions. When Ariadinvestor sits in the court room, the prosecutor will list his thousand user names.
Will I have a chance to sit in the court room? Lisa: "I will crush any that pretend to be Ariadinvestor. Yahoo Admin M impersonates me! Lisa: "Ariadinvestor is an angel.
Do not speak against him or you will be struck down by me He has spelled it out for all to see. SRNE is what he predicted gold bags. Look at his post history. He has been here a very very long time. Ariadinvestor is a generous gentle genuine gold bag genius!! Who in here actually is doing well trading stocks? I always seemed to miss my buy and sell points.
Until I found this platform that seems to help out. I recommend it. Now this investment could help you find a potential or even find some of that gold they seek!Watch CBS news special video below. The combined capacity would support the rapid scale-up and sustained production of the novel cell therapy.
Many signs lead me to believe there will be an exponential return on Sorrento Stock in the near future; the analysts opinions, the pipeline, Scilex IPO, new partnerships, COVID clinical trial, a likely windfall legal recovery, robust institutional and insider buying.
Read here for a much more detailed analysis on Sorrento Therapeutics which is recognized as one of 30 companies offering a possible cure. I believe Sorrento offers more upside than any other biotech for Biobetter means that as a generic it is even better than the branded drug. Currently there was only one drug approved as a biobetter.
They should have an answer by the end of the year. There are new regulations being put in place by FDA for those type of drugs and they are pushing towards accepting more as it will help to drive drug prices down. The company media relations clearly doesn't know how to use correct headlines for press releases. Please do your own due diligence before buying or selling any stock.
Celularity CBS News interview. Sorrento Therapeutics stock price is ridiculously cheap.Select Your Market.
Your losses are our losses too. The Sorrento Therapeutics stock gained 0.
Sorrento Therapeutics, Inc. (SRNE)
During the day the stock fluctuated 5. The price has been going up and down for this period, and there has been a You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled.
Given the current short-term trend, the stock is expected to rise 5. The Sorrento Therapeutics stock holds buy signals from both short and long-term moving averages. In addition, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. A breakdown below any of these levels will issue sell signals.
Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Monday August 10,and it has fallen so far Further fall is indicated until a new bottom pivot has been found.
This stock may move very much during a day volatility and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk".
For the last week, the stock has had daily average volatility of 6. There is a sell signal from a pivot top found 43 day s ago. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Sorrento Therapeutics stock to perform well in the short-term.
The sentiment is based upon votes on StockTwits. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.The owners of the converted debt are mostly BVI funds with little online footprint.
What little footprint there is, it is tied to Sorrento. Sorrento Therapeutics, Inc.SORRENTO THERAPEUTICS INC SRNE STOCK CHART ANALYSIS
The market clearly has some reservations over the likelihood of a formal bid occurring. But there may be an even simpler reason as to why the stock sold off after the initial spike at the open. This timely bid announcement occurred just three days after SRNE filed an amended S-3 statement to sell 17, shares by selling stockholders.
This is approximately SRNE will not be receiving any proceeds from the sale, but the origins of the sale become rather curious when reading the S-3 filing:. On November 8,the convertible promissory notes were amended pursuant to that certain Note Conversion Agreement, dated as of November 8,by and among us and the Selling Stockholders, or the Note Conversion Agreement.
We are registering the resale of 17, of the Shares as required by the Note Conversion Agreement. The increase in shares that were issued due to the lowered conversion rate equals the 17, shares that have been registered in the most recent S-3 filing. Investors have to be cognizant of the timing of all this. The amended conversion rate came just two weeks before the initial two bids were announced.
What lucky timing for these convertible debt holders! Who are the selling stockholders that benefited from this timely conversion right before these takeover bids were announced? Here is the list:. Based on the names, they appear to be funds with roots in China and the Asia-Pacific region. It's hard to find much information on them, and an internet search reveals that any online footprint is tied to Sorrento in some way.
Of the six funds, I found two of them registered with the SEC. They have disclosed no other investments. I will let readers come to their own conclusion as to the origins of these funds. A short seller by the name of J Capital Research released a bearish report on Sorrento in Here is an excerpt from that report:. The same focus on insider benefits is in evidence in the Chinese financing deals.
The short seller had an obvious agenda in the report. I wrote this article myself, and it expresses my own opinions.
I am not receiving compensation for it other than from Seeking Alpha. I have no business relationship with any company whose stock is mentioned in this article. SRNE has been on the rise in the last few months since talk of multiple takeover bids.Current Investors: If you are dissatisfied with management, now is a good time to take profits.
Data by YCharts. The results are preliminary and still require validation in the form of clinical trials and peer-review. But the science is compelling and the potential financial upside changes my previous recommendation of an across the board hold rating to a buy rating, for those non risk-averse investors seeking a possible home run from a clinical-stage bio-pharmaceutical. Historically, Sorrento branded itself as a company focused on two verticals, immuno-oncology and pain management but at its heart, it is an antibody company.
An antibody is a protective protein produced by the immune system in response to the presence of a foreign substance, to paraphrase Encyclopedia Britannica. Cancer cells, bacteria, and viruses, like the one that causes COVID, are foreign substances and therefore, theoretically can be impeded or neutralized by antibodies.
A vaccine is meant to safely expose a person's body to a pathogen to teach it to create these neutralizing antibodies. This allows the approach to be administered to healthy and infected people alike.
This therapy would effectively be a limited-duration vaccine and could be administered pre-exposure, conferring temporary immunity to COVID if a person is exposed. This means additional debt will need to be secured to run business operations, implying Sorrento has a long way to go before the company hits profitability. I preface this section with the disclaimer that I am not implying the global pandemic is a good thing for Sorrento, only that COVID is caused by a virus that has no known cure.
Both products mentioned above are based on the premise that antibodies will be injected into the body, bind to the S1 protein spike of the coronavirus that causes COVID, and prohibit the virus from leveraging the ACE2 receptor site to infect human cells. Source: Encyclopedia Britannica. Below is an account of the potential revenue impact, if either or both products in the press release become viable treatments to combat COVID This product would use a combination of 10 antibodies and effectively be a vaccine used as a prophylactic treatment to prevent initial infection.
Using the Swine Flu global pandemic as an imperfect, yet meaningful guide for the demand of a COVID therapy, we can back into the net income impact to Sorrento. Three billion doses of the Swine Flu vaccine were created and available for distribution to the world's 6. This product would be based on a single antibody, which Sorrento says eliminates a COVID infection completely, in 4 days. Adjusting by In addition to the exciting news released last week, Sorrento is pursuing multiple avenues in the fight against SARS-CoV-2, which can be divided into three categories.
The second category is the most straightforward, the search for an outright vaccine. Protecting non-infected cells would prevent the virus from progressing to its most advanced state. The approach repurposes a proven technique used to produce cancer vaccines.
The technique involves leveraging, reproduction-deficient cells from a rare type of leukemia known as Erythroleukemia. Source: Science Direct.
Source: Arizona State University. The resulting vaccine would be applied via an intramuscular injection similar to a flu-shot.
If successful, this approach benefits older populations who do not respond as well to traditional vaccines with the added benefit of reducing potentially harmful side effects. The difference is that CMAB binds to COVID in two places, potentially blocking the receptor binding domain and could mitigate lung inflammation and cytokine storm while increasing blood flow to affect lung tissue and normalize blood pressure. Source: Mabpharm Website. Sorrento Therapeutics is a tale of 3 investors.
Depending upon your goals and risk profile I have three different recommendations:. In many cases, long-standing protocols are being relaxed in order to speed the development process.
I recommend buying Sorrento for those investors that understand the risk of investing in clinical-stage biopharmaceutical companies but are looking for a homerun. If you are not currently invested in Sorrento and you are a value investor, the fundamentals have not changed.
Sorrento still has a heavy debt load, light revenue, and opaque investor relations. Now is not the time to initiate a new position.